These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30235833)

  • 21. Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain.
    Poirier S; Hamouda HA; Villeneuve L; Demers A; Mayer G
    PLoS One; 2016; 11(6):e0157230. PubMed ID: 27280970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifying pH-sensitive PCSK9/LDLR interactions as a strategy to enhance hepatic cell uptake of low-density lipoprotein cholesterol (LDL-C).
    Ben-Naim L; Khalaila I; Papo N
    Protein Eng Des Sel; 2022 Feb; 35():. PubMed ID: 35174858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
    Brousseau ME; Clairmont KB; Spraggon G; Flyer AN; Golosov AA; Grosche P; Amin J; Andre J; Burdick D; Caplan S; Chen G; Chopra R; Ames L; Dubiel D; Fan L; Gattlen R; Kelly-Sullivan D; Koch AW; Lewis I; Li J; Liu E; Lubicka D; Marzinzik A; Nakajima K; Nettleton D; Ottl J; Pan M; Patel T; Perry L; Pickett S; Poirier J; Reid PC; Pelle X; Seepersaud M; Subramanian V; Vera V; Xu M; Yang L; Yang Q; Yu J; Zhu G; Monovich LG
    Cell Chem Biol; 2022 Feb; 29(2):249-258.e5. PubMed ID: 34547225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction.
    Sun H; Wang J; Liu S; Zhou X; Dai L; Chen C; Xu Q; Wen X; Cheng K; Sun H; Yuan H
    J Chem Inf Model; 2021 Oct; 61(10):5269-5279. PubMed ID: 34553597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First Food-Derived Peptide Inhibitor of the Protein-Protein Interaction between Gain-of-Function PCSK9
    Grazioso G; Bollati C; Sgrignani J; Arnoldi A; Lammi C
    J Agric Food Chem; 2018 Oct; 66(40):10552-10557. PubMed ID: 30226051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ; Hooper NM
    Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Black Raspberry Extract Enhances LDL Uptake in HepG2 Cells by Suppressing PCSK9 Expression to Upregulate LDLR Expression.
    Song KH; Kim YH; Im AR; Kim YH
    J Med Food; 2018 Jun; 21(6):560-567. PubMed ID: 29569973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.
    Wang WZ; Liu C; Luo JQ; Lei LJ; Chen MH; Zhang YY; Sheng R; Li YN; Wang L; Jiang XH; Xiao TM; Zhang YH; Li SW; Wu YX; Xu Y; Xu YN; Si SY
    Acta Pharmacol Sin; 2024 Oct; 45(10):2119-2133. PubMed ID: 38811775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Butein Synergizes with Statin to Upregulate Low-Density Lipoprotein Receptor Through
    Hwang JT; Kim HJ; Choi HK; Park JH; Chung S; Chung MY
    J Med Food; 2020 Oct; 23(10):1102-1108. PubMed ID: 32835593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAQR3 modulates blood cholesterol level by facilitating interaction between LDLR and PCSK9.
    Huang M; Zhao Z; Cao Q; You X; Wei S; Zhao J; Bai M; Chen Y
    Metabolism; 2019 May; 94():88-95. PubMed ID: 30831144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of PCSK9 inhibition and its effects beyond LDL receptors.
    Dixon DL; Trankle C; Buckley L; Parod E; Carbone S; Van Tassell BW; Abbate A
    J Clin Lipidol; 2016; 10(5):1073-80. PubMed ID: 27678423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study.
    Valenti V; Noto D; Giammanco A; Fayer F; Spina R; Altieri GI; Ingrassia V; Scrimali C; Barbagallo CM; Brucato F; Misiano G; Cefalù AB; Averna MR
    Atherosclerosis; 2020 Jan; 292():209-214. PubMed ID: 31564372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.
    Galvan AM; Chorba JS
    J Lipid Res; 2019 Jan; 60(1):71-84. PubMed ID: 30463987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy.
    Xu M; Lei G; Chen M; Wang K; Lv W; Zhang P; Hu T; Gao J; Lu C; Mei Y; Xu Z; Bai Z; Hu H; Jiang Y; Tan S
    EBioMedicine; 2021 Mar; 65():103250. PubMed ID: 33647772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.
    Winston-McPherson GN; Xie H; Yang K; Li X; Shu D; Tang W
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2345-2348. PubMed ID: 31227343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.